These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34946271)

  • 41. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R; Evangelista ML; Amadori S
    Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
    Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
    Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
    Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.
    Grainger JD; Blanchette VS; Grotzinger KM; Roy A; Bussel JB
    Br J Haematol; 2019 Apr; 185(1):102-106. PubMed ID: 30592022
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
    Haselboeck J; Kaider A; Pabinger I; Panzer S
    Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.
    Visco C; Rodeghiero F; Romano A; Valeri F; Merli M; Quaresimini G; Volpetti S; Santi RM; Carli G; Lucchini E; Passamonti F; Rambaldi A; Motta G; Borchiellini A; d'Amore ESG; Ruggeri M
    Blood; 2019 Nov; 134(20):1708-1711. PubMed ID: 31570488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient.
    Andic N; Gunduz E; Akay OM; Şahin D; Teke HÜ
    Platelets; 2014; 25(1):69-70. PubMed ID: 23320868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?
    Vlachaki E; Sousos N; Perifanis V; Kaiafa G; Onoufriadis I; Hatzitolios A; Boura P
    Acta Haematol; 2015; 133(1):78-82. PubMed ID: 25170628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute kidney injury and nephrotic syndrome associated with eltrombopag therapy in chronic idiopathic thrombocytopenic purpura.
    Ghosh SA; Patrick J; Maw KZ
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33827880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Catastrophic anti-phospholipid syndrome with Libman-Sacks endocarditis following eltrombopag therapy for immune thrombocytopenic purpura: A case report.
    Dichtwald S; Meyer A; Ifrach N
    Lupus; 2021 Dec; 30(14):2304-2309. PubMed ID: 34923861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
    González-López TJ; Fernández-Fuertes F; Hernández-Rivas JA; Sánchez-González B; Martínez-Robles V; Alvarez-Román MT; Pérez-Rus G; Pascual C; Bernat S; Arrieta-Cerdán E; Aguilar C; Bárez A; Peñarrubia MJ; Olivera P; Fernández-Rodríguez A; de Cabo E; García-Frade LJ; González-Porras JR
    Int J Hematol; 2017 Oct; 106(4):508-516. PubMed ID: 28667351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
    Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
    Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study.
    Lucchini E; Palandri F; Volpetti S; Vianelli N; Auteri G; Rossi E; Patriarca A; Carli G; Barcellini W; Celli M; Consoli U; Valeri F; Santoro C; Crea E; Vignetti M; Paoloni F; Gigliotti CL; Boggio E; Dianzani U; Giardini I; Carpenedo M; Rodeghiero F; Fanin R; Zaja F;
    Br J Haematol; 2021 Apr; 193(2):386-396. PubMed ID: 33618438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eltrombopag for use in children with immune thrombocytopenia.
    Kim TO; Despotovic J; Lambert MP
    Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.